Boston area's highest-profile clinical trial failures of 2009 . And a big part of the Lexington, MA-based company's recovery has been to learn from the failure and advance other drug candidates in its pipeline. After Synta halted its pivotal trial of the drug elesclomol for patients with a deadly form of skin cancer in February 2009, the firm saw its common stock value fall more than 80 percent in a day.
FULL ARTICLE AT The Motley Fool